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Running title:  
Seizures, SUDEP & ID  
 
Highlights 
 Service evaluation of intellectual disability (ID), epilepsy & SUDEP risk factors  
  
 Examines holistic care in a non-epilepsy managing UK urban community ID service 
 20% in the ID cohort had seizures consistent with expected 22.5% prevalence  
 Significant multi-morbidity, polypharmacy, SUDEP risk & lack of care plans found 













Purpose: This study identifies epilepsy related characteristics and SUDEP risk factors in 
people with epilepsy (PWE) open to an urban community ID service in the UK where 
managing epilepsy is not part of the service remit, to understand the holistic care provided to 
this vulnerable population. 
Methods: Electronic record database search in a north London community ID service 
(catchment population approx. 290,000) identified relevant ID/epilepsy characteristics in 
PWE to compare those with mild ID to moderate-profound ID.  Patients, their families/carers 
were administered the SUDEP and Seizure Safety Checklist (“Checklist”). Risk management 
comparison was made to similar data from Cornwall UK where PWE are supported within 
the ID service and the Checklist used annually.  
Results: Fifth (137/697) of people open to the service, had epilepsy. Over 3/4 had 
moderate-profound ID. Neurodevelopmental disorders were coexistent in 2/3, psychiatric 
conditions in 1/3 of which 1/4 had psychosis. Mean number of anti-seizure drugs was 1.45 ± 
0.98 with 1/4 on psychotropics. Over a third did not have an epilepsy care plan. None 
contacted (n =103) had SUDEP awareness.  Median Checklist risk factors were seven (IQR 
4.5 - 9). A third had experienced seizures lasting >5 mins or status epilepticus. In 
comparison to the Cornish ID data significant differences were evident in four of seven 
modifiable risk factors.   
Conclusions: This real world study highlights complexity and risks of PWE and ID. A lack of 
“joined up” approach can undermine this vulnerable population safety. Person centred risk 
communication and care plans are easily achievable and essential. 
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Intellectual disability (ID) is defined as a significant impairment of intellectual function and 
adaptive behaviour, developing before 18 years of age1. People with ID have higher rates of 
morbidity and mortality than those without ID2,3. The reasons for this are multifactorial and 
range from higher prevalence of co-morbidity to barriers accessing suitable services4,5.  
Epidemiological studies suggest that 20-25% people with ID have epilepsy6 compared to 
0.5-1% in the general population7. There is a positive correlation between increasing ID 
severity and  seizure prevelance8.  
The recent national enquiry into premature mortality in people with ID has shown that people 
with ID can die up to 25 years earlier than the general population. A major direct and 
contributory cause is epilepsy. Five percent of people died as a direct result of seizures and 
seizures were an associated condition in 45% of all premature deaths9. Sudden Unexpected 
Death in Epilepsy (SUDEP) is considered to be three to nine-fold higher in ID than general 
populations10.  
People with ID and epilepsy are associated with higher levels of mental illness, 
neurodevelopmental conditions co-morbidity and irrational polypharmacy11.The management 
of epilepsy in adults with ID is therefore complex and there is a paucity of research or real 
world evidence of the nature and degree of clinical complexity, drug prescribing, risk 
assessments and patterns of care of people with ID and epilepsy as compared to general 
population4,5,12.  
Aim: -  
1. To identify and characterise, current standards of care, prescribing and risk assessments 









2. To inform if there is a difference in the above characteristics between those with mild ID to 
moderate to profound ID  
 
METHODS 
The STROBE checklist (supporting file) was used to guide the cross sectional study. This 
study was conducted between May – June 2019 in a community ID service comprising 
multidisciplinary professionals: psychiatrists, psychologists, social workers, speech and 
language therapists, occupational therapists and ID nurses as a quality improvement project 
to improve care for people with ID and Epilepsy open to services. The population served is 
an inner London borough covering a catchment population of approximately 290,000. In this 
area, epilepsy management is largely in primary care with access to secondary and 
quaternary neurology services at local hospitals depending on general practitioner (GP) 
referral. The study was registered with the local NHS Trust audit department (registration 
number: 256855). The NHS Health research authority tool (http://www.hra-
decisiontools.org.uk/research/index.html) was used to confirm that no ethics is needed for 
this project (Supplementary File 1). The project was co-designed with SUDEP Action, 
Patient and Public Involvement lead for the project.  
A search of the electronic record database (Mosaic, Servelec) of the ID specialist service 
using the terms: “epilepsy”, “seizure” was conducted. The database had people presently 
open to the ID service. All patients aged 18 or older with an ID identified by the search were 
included.  
By case note review, individual data: 
1. Demographics (age, gender)  
2. Level of ID – this was divided as per the ICD criteria1 into 2 groups: mild ID and 









By descriptive statistics, compilation data: 
3. Number of those experiencing mental or behavioural disorders, genetic disorders, 
and neurodevelopmental disorders (ASD, ADHD) according to ICD/DSM diagnosis. 
4. Number prescribed psychotropic medication (anti-psychotic and non-anti-psychotic). 
The British National Formulary (BNF) was used to define the category of the specific 
nature of the drug13.  
The SUDEP and Seizure Safety Checklist (“Checklist” - managed by SUDEP Action & 
available via https://www.sudep.org/checklist) is a validated structured tool which outlines 
risk factors both modifiable and non-modifiable which increase the risk of SUDEP and 
undermine seizure safety14. Tool description is provided in Supplementary File 2. Each PWE, 
their families/carers were contacted by telephone to discuss and record risk factors using the 
SUDEP and Seizure Safety Checklist (Table 1). Each contact was asked whether the PWE 
had an epilepsy care plan.  
Contact was made only with those who were open to the clinicians of the specialist service 
and being regularly reviewed for ID related needs. As NICE since 2003 and all good practice 
national and international epilepsy guidance has advocated that SUDEP and epilepsy 
related risk issues be discussed for any PWE, the expectation was that the population 
contacted would be SUDEP aware.  The discussion on SUDEP was done to elicit person 
centred understanding of risk as part of their clinical support.  The guidance provided by the 
Royal College of Psychiatrists in how to have a sensitive conversation around epilepsy risk 
and SUDEP was followed4.  A trainee psychiatrist contacted all the eligible PWE (i.e. those 
open to the service) as part of a planned clinical review. He discussed their current well-
being and ongoing health needs and on the matter of seizures offered to discuss specific 
person centred factors of seizure risks. The discussion was facilitated by the Checklist. 
SUDEP was explained in the context of the discussion. On completion feedback was given 









anytime post diagnosis of seizures. Further inquiry was made if SUDEP or epilepsy risk was 
mentioned or remembered irrespective of lack of specifics. Interviewees were asked to again 
contact the services if they felt anxious or confused about the conversation and discussion 
had.  
Comparison of the risk factors was undertaken with similar data from Cornwall UK.  There a 
clinic specialized in epilepsy and intellectual disability (ID) has had discussion of SUDEP and 
seizure risk as part of routine practice since 2010. The administration of the Checklist 
happens annually. The Checklist was administered by an epilepsy nurse or by a specialist 
who had training in doing so. The Checklist data set is registered as part of an ongoing 
rolling audit to inform on service outcomes.  The last available checklist data set was used.  
Statistical analysis  
Data are presented descriptively in the form of summary measures by cohort (and total 
sample population). The binary risk factors are summarized as relative frequencies and the 
total risk score by the median and interquartile range. Pearson’s Chi Squared test with p-
values computed by Monte Carlo simulation was used to explore associations between the 
level of ID and the clinical factors. Comparison was made between those with mild ID and 
those with moderate to profound ID for all domains.  Bonferroni adjustment was performed to 
address multiple testing. The threshold set for statistical significance was p = 0.0025.  
Further comparisons of risk factor prevalence between the study cohort and a previous 
cohort from Cornwall UK were conducted using the Chi Squared test with simulated p-values 
to inform discussion. No baseline comparison between these two populations (London and 
Cornwall) was done at the start of the project.  
RESULTS 
137 out of 697 (20%) adults with ID open to the service had a diagnosis of epilepsy as 
identified by the search. None were under the review of the service for epilepsy. Data was 









was 1.86: 1 (male: female). 24 (1:67: 1) had mild ID and 79 (1.93: 1) had moderate-profound 
ID. There were co-existent neurodevelopmental disorders (autism, ADHD) in 71 (2.55: 1). 34 
(1.83: 1) had some form of co-existent mental disorder and 16 (1.29: 1) had a genetic 
disorder.  
Eighty-five out of 103 patients (83%) experienced generalised tonic clonic seizures (GTCS), 
seven (7%) had focal seizures, 11 (11%) had unknown seizure phenotype. Forty-nine had a 
GTCS in the last year. Forty-six (45%) had a seizure in the last six months. 11 (11%) 
reported having a seizure more than once a month and 21 (20%) had a seizure more than 
once a week. In this cohort, patients were on a mean number of 1.45 ± 0.98 anti-epileptic 
drugs (AEDs), 23 (22%) were on antipsychotics and 11 (10%) on other psychotropics. 26 
(25%) patients had AED compliance issues. Only 61 (59%) of patients had an epilepsy care 
plan. A third had previously met the definition for status epilepticus15.  
Co-existing mental health problems was more likely associated with mild ID (n= 14, 58%). 
Nearly 25% (n =6) of this subset had seizures more than once a month and AED compliance 
issues. Only 15 (44%) had an epilepsy care plan.  
In those with a neurodevelopmental disorder, 16 (22%) had a seizure more than once a 
month and 14 (20%) had a seizure more than once a week. Eight (11%) had an issue of 
AED compliance. 41 (58%) had an epilepsy care plan. Of specific interest is that those with 
neurodevelopmental co-morbidity were more likely to experience higher frequency of 
seizures monthly than those without (42% vs. 31%). 
 
SUDEP and Seizure Risk Factors  
None of the 103 people who agreed to be contacted were neither aware of SUDEP nor the 
risks for SUDEP. The median total number of risk factors was 7 (IQR 5 – 9). There was a 
median of 5 (IQR 4 – 5) non-modifiable risk factors and 3 (IQR 1 – 4.5) modifiable risk 









profound ID groups for total, modifiable or non-modifiable factors (Table 2/Figure 1). 
Likewise, no significant difference existed on risk factors when those with 
neurodevelopmental disorders were compared with those without (Figure 2).  Over 90% of 
patients had at least 1 modifiable risk factor for seizures and SUDEP (Table 3).  
46 (45%) of patients reported nocturnal seizures, of those 10 (22%) did not have any 
nocturnal surveillance. Those who did have seizure surveillance at night, had audio-visual 
monitoring (n =18), physical checks (n = 9) or other monitoring modalities (n = 9).  
No contact at the end of the interview told of any distress or anxiety from the discussion. No 
calls for further information, clarification or distress, were received post discussion either to 
SUDEP Action who provide a helpline support or to the clinical service.   
Cornwall Data –  
The Cornish ID sample (n =129) was drawn from approximately 300,000 catchment 
population. The up to date (till 2018) SUDEP and Seizure Checklist data of all eligible 129 
PWE and ID of a total of 169 PWE open to the service was used. All PWE had at least two 
Checklist reviews on file. When contact had been made to update the Checklist with the 129 
PWE and/or their carers inquiries had been made of preliminary awareness and risks of 
SUDEP including recollection of the previous discussion. All 129 PWE and/or their carers 
were SUDEP aware.  There were 75 males (58%) and 54 females (42%).Mean age was 37 
(SD: 14). Duration of epilepsy was greater than 15 years for 117 PWE (91%) with three (2%) 
having had seizures for 10-15 years, one for 5-10 years and seven (5%) for less than five 
years.   Generalised seizures were present in 87 (68%). Mean AEDs in this cohort was 2.2 ± 
1. Compliance concerns were present in 14 people (11%) while one person had a reported 
alcohol problem.  
A brief comparison was made to findings of using the Checklist in the two cohorts (Table 4). 
While no differences were found in the non-modifiable factors, significant differences existed 









(p<0.001), less seizures lasting more than 5 min/Status Epilepticus (p =0.002), more 
presence of surveillance at night (p =0.02), and lesser presence of concurrent psychiatric 
disorder (p<0.001) than the London cohort.  
 
 DISCUSSION 
This small real-world study characterises the seizure profiles and risk factors for SUDEP of 
people open to an urban integrated ID service in an inner borough of London. The service is 
led by psychiatrists with no commissioned role or remit for epilepsy. In this area, there are 
secondary and quaternary neurology services; however there is no integrated epilepsy care. 
This model is consistent with many other urban areas in the UK16.  
The prevalence of epilepsy in this study was concordant with previous studies at 20%8. The 
findings that a third of people had a major mental health condition, more than two thirds  
neurodevelopmental disorders (ASD and ADHD), high proportions of genetic disorders and 
prescribing of anti-seizure drug and psychotropic polypharmacy is consistent with other 
studies and reports4,5. The study again highlights that polypharmacy, particularly the drug 
burden of AEDs and psychotropics is a developing issue of concern in this vulnerable 
population and attempts need to be made to consider active deprescribing to reduce the 
burden of iatrogenic harm17,18,.  
Those with co-morbidity such as a neurodevelopmental condition had higher health burden 
particularly more seizure frequency. Of concern, is that the whole cohort had ongoing 
seizure activity thus highlighting the high burden of risk. Inspite of this and the added 
outlined health complexities nearly two thirds did not have a basic epilepsy care plan.   
None of those contacted (n =103) knew of SUDEP or recalled any clinician discussing this 
with them. Due to the lack of an integrated neurology service it was not possible to verify if 









such a discussion, it is clear that there is no recall. This reiterates the developing evidence 
for having person centred risk discussions regularly19-220.  
More than 60% of this cohort had a modifiable risk factor. In particular, the presence of high 
risk SUDEP factors such as nocturnal seizures (53%) and lack of surveillance at night (27%) 
in a significant number of people was a concern.  Recent evidence is suggestive of nocturnal 
seizures and the type of supervision being an increased SUDEP risk for people with ID23. 
There is evidence that regular communication of SUDEP and seizure risk improves seizure 
related outcomes including in people with ID24.  The Cornish sample had been receiving 
regular risk information periodically for over five years. While the burden of non-modifiable 
risk between the two populations was similar there were significant differences in important 
modifiable risk factors such as episodes of status, nocturnal surveillance, psychiatric 
disorders and the use of emergency services. This could indicate that regular 
communication of risk change is associated with mitigation of modifiable risk factors.   
This pragmatic real-world study is not without limitations. This was a cross-sectional 
explorative study looking at real world practice. The study lacks definitive comparable 
samples, there is a lack of definitive seizure details, no seizure outcome data, no historical 
data on drug use and no attempt has been made to validate psychiatric diagnosis.  The level 
of seizure control has not been looked and could be a possible confounder to the prescribing. 
Further limitations include the study being retrospective, involving data collection from 
clinical records, clinician attributes and practice standards. Limitations in diagnosis and 
classification have been minimised by using consistent recognised diagnostic standards and 
rationale (Appendix 1)  
CONCLUSION 
Increasingly, there is recognition that people with ID and epilepsy are a marginalized 
vulnerable group. However, few studies exist which quantify the problem. This is one of the 









ID and epilepsy to describe their characteristics and management issues. Our results 
contrast with what we would expect for epilepsy in the general population. The findings 
suggest that while the epilepsy needs of people with ID is significant there is a need to 
consider role of treatment resistance, multimorbidity and polypharmacy and in particular 
issues of risk communication as evidenced by this study.  
Particular attention should be given to eliciting the history of nocturnal seizures which 
increase risk significantly of SUDEP and stress the importance of nocturnal monitoring 
particularly use of suitable audio or video monitors25, 26. While the evidence to support 
nocturnal monitoring to mitigate SUDEP risk is developing and needs to be balanced on the 
potential of invading an individual’s privacy it needs to be weighed in best interest to that 
many people with ID could struggle to understand and communicate any events which occur 
to them at night thus requiring a higher level of attention and surveillance to mitigate the 
harm risk.   
Interestingly, providing and reviewing basic risk communication regularly and ensuring 
suitable care plans which do not require any major epilepsy specialism or resource can 
significantly improve care and safety.  
However, to deal with the more complex issues of multi-morbidity and polypharmacy a 
concerted multidisciplinary approach with a holistic view on quality of life and safety might be 
needed to provide more satisfactory individually centred outcomes.  
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Appendix 1: Rationale for examining the mild and moderate- profound ID as two 
groups:  
1. Epilepsy possibly due to disturbed brain function is present in 30 - 50% of the 
moderate to profound ID group as compared to 8-12% in the mild  ID population and 
0.6 -1% in general population27 -29. 
2. Moderate to profound ID have a low prevalence and together they would combine 
to form 15% of the total ID population30.  Taken individually it would be difficult to 
achieve satisfactory power to deliver meaningful conclusions.  
3. Moderate to profound ID is difficult to assess and classify which causes significant 
issues with accuracy of specific diagnosis of severe or profound ID.   
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Table 1 – SUDEP and Seizure Safety Checklist (adapted from https://sudep.org/checklist) 
Modifiable risk factor  Non-modifiable risk factor  
Lack of clinical review of epilepsy in last 12 
months 
Early onset of epilepsy (<16 years old) 
Active seizures: seizures in last 12 months Duration of epilepsy (>15 years) 
Convulsive seizures: generalised tonic 
clonic seizures in 12 months 
Young age (20-40 years old)  
Uncontrolled seizures (had seizures 
lasting >5 mins/status epilepticus) 
Male sex 
Seizure frequency  Intellectual Disability 
Nocturnal seizures  
Lack of night surveillance  
Sleeping in prone position  
Anti-epileptic drug compliance issues  
Frequent anti-epileptic drug changes  
Alcohol/drug misuse  
Psychiatric disorder  













Table 2 – Distribution of risk factors by ID severity   
Risk factor ID severity  
 Mild (N=24) Moderate to 
profound (N=79) 
 
 n % n % p-value* 
Epilepsy > 15 yr 20 83 66 87 0.74 
Dx aged < 16 yrs 20 91 61 85 0.52 
Current age 20-40 yrs 15 63 48 61 1.00 
Male sex 15 63 50 63 1.00 
ID present 24 100 79 100 1.00 
Childbearing age and 
received preconception 
counselling 
4 44 4 13 0.05 
Used A&E/999 11 48 39 50 1.00 
Review in last 12 months 13 54 47 59 0.81 
Seizure in last year 11 46 45 57 0.37 
GTCS in last year 7 29 28 35 0.63 
Seizures >5 min/status 
epilepticus 
7 30 29 37 0.63 









Surveillance at night 7 54 31 67 0.50 
Prone position 0 0 5 13 0.58 
Difficulty with compliance 6 26 5 7 0.02 
Frequent AED changes 3 13 4 5 0.36 
Psychiatric disorder 14 58 21 27 0.007 
Abuse alcohol 2 8 1 1 0.13 
Take recreational drugs 1 4 1 1 0.43 
Review booked 12 50 45 57 0.62 
 
*Bonferroni threshold for statistical significance is p=0.0025 
Potentially modifiable risk factors 














Table 3 - Prevalence of modifiable v non-modifiable risk factors by ID severity  
Risk factor 
grouping 
ID severity  
 Mild (N=24) Moderate to profound 
(N=79) 
 
 n % n % p-value 
Modifiable 24 100 70 89 0.11 
Non-
modifiable* 













Table 4 – Comparison of Risk Factor Prevalence between London and Cornwall 
Risk factor Population  
 London (N=103) Cornwall (N=130) P value  
 n % n %  
Non-Modifiable Risk Factors       
Epilepsy lasting over 15 years 86 86% 117 91% 0.20 
Diagnosed before age of 16 
years 
81 86% 115 89% 0.54 
Current age being between 
20-40 years 
63 61% 64 50% 0.08 
Male sex 65 63% 75 58% 0.50 
Modifiable Risk Factors       
Used Emergency services i.e. 
Paramedics/ED in last  year 
50 50% 18 14% <0.001 
Seizures lasting more than 5 
min/status epilepticus 
36 35% 22 17% 0.002 
surveillance at night 38 64% 101 81% 0.02 
Difficulty with compliance 11 11% 14 11% 1.00 
Frequent AED changes 7 7% 9 7% 1.00 
concurrent psychiatric disorder 35 34% 13 10% <0.001 











































Figure 2 – Box and whisker plots of total number of risk factors by presence of 
neurodevelopmental disorder 
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